



**Exclusive International Product Distribution Agreement**  
**Episciences, Inc. signs landmark agreement with Rohto Pharmaceutical Co., Ltd.**

**FOR IMMEDIATE RELEASE**

**March 7, 2006**

**Contact:** Trish Stack 208/863-2396 [trish@epionce.com](mailto:trish@epionce.com)

**BOISE, Idaho – Episciences, Inc.**, developer and manufacturer of the **Epionce®** brand of cosmeceutical and non-prescription dermatological products has entered into an agreement with **Rohto Pharmaceutical Co., Ltd.**, Osaka, Japan, a publicly traded manufacturer and marketer of pharmaceutical and other healthcare related products worldwide.

The purpose of the agreement is threefold: to grant Rohto Pharmaceutical Co., Ltd. the exclusive rights to distribute the Epionce® brand of skin wellness products throughout Japan, to establish a partnership in marketing skin care products specifically for the Japanese market and to foster a long term relationship between the companies. Episciences, Inc. is in the process of planning the expansion of its manufacturing and administrative facilities as well as personnel requirements to accommodate the significant growth that this deal will represent to current operations. The products to be sold in Japan will be manufactured and packaged at the company facilities in Boise, Idaho and exported to that country. The Japanese market introduction is anticipated for early 2007.

Dr. Carl R. Thornfeldt, Episciences, Inc. Co-Founder and CEO, commented, “We welcome our new partner in our common efforts to expand the Epionce® consumer base. This deal further cements our mission to deliver on the promise of bringing to all markets a skin wellness product line based on clinically documented principles and performance. Extensive resources, profound expertise and lengthy achievements in our industry make Rohto Pharmaceutical Co., Ltd., the ideal partner to successfully promote our products in Japan.”

###

**About Episciences, Inc:**

Episciences, Inc, was founded in 2002 and is based in Boise, Idaho. Episciences, Inc, integrates twenty-plus years of research into the development of a highly effective cosmeceutical, non-prescription, dermatological product line. This breakthrough product has been proven effective by 13 independent clinical studies to reverse and prevent the effects of visible skin aging and certain common skin diseases. For more information, visit our website at [www.epionce.com](http://www.epionce.com).

**About Rohto Pharmaceutical Co., Ltd.:**

Rohto Pharmaceutical Co., Ltd. is among the largest manufacturers and marketers of pharmaceutical and other healthcare related products in Japan. Founded in 1899, the company is based in Osaka, Japan. Production sites include facilities in the U.S., Europe, Latin America, China and Southeast Asia with product distribution to over 150 countries including all of Asia, the Americas and Europe. In 1988 Rohto Pharmaceutical Co., LTD. acquired management rights to prominent U.S. manufacturer, The Mentholatum Company, Inc. Corporate sales revenue in 2004 exceeded \$800 million. The President and CEO, Mr. Kunio Yamada, is a fourth generation company executive. For more information please visit the Rohto website: [www.rohto.co.jp/global](http://www.rohto.co.jp/global)